famotidine has been researched along with Peptic Ulcer in 96 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients without ulcers or erosive oesophagitis on endoscopy at baseline were randomly assigned by computer-generated randomisation sequence to receive famotidine 20 mg twice daily (n=204) or placebo twice daily (n=200)." | 9.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| "Little is known about the efficacy of H(2)-receptor antagonists in preventing recurrence of aspirin-related peptic ulcers." | 9.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
| "The aim of this study was to evaluate the effect of famotidine, a histamine receptor antagonist on corpus gastritis in patients with peptic ulcer disease." | 9.11 | Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease. ( Chayama, K; Haruma, K; Hata, J; Ito, M; Kamada, T; Kawamura, Y; Kusunoki, H; Sugiu, K; Tanaka, S, 2005) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 9.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "One hundred four patients with rheumatoid or osteoarthritis who had gastroduodenal ulceration received famotidine, 40 mg twice daily." | 9.08 | Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. ( Cottrell, J; Hawkey, CJ; Hudson, N; Mann, SG; Russell, RI; Sturrock, RD; Swanell, AJ; Taha, AS; Trye, P, 1997) |
| " We conducted a cross-sectional study to compare the prevalence of gastroduodenal ulcers or erosions in patients taking LDA with either 40 mg/day of famotidine or 15 mg/day of lansoprazole for at least three months." | 7.79 | Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2. ( Kadota, J; Murakami, K; Tamura, A, 2013) |
| "The purpose of this study was to assess the incidence and clinical significance of famotidine-associated thrombocytopenia in the trauma patient population." | 7.77 | Famotidine use and thrombocytopenia in the trauma patient. ( Compoginis, JM; Gaspard, D; Obaid, A, 2011) |
| "A total of 30 patients (29 with peptic ulcer and 2 with erosive gastroduodenitis) received lecedil, a new famotidine blocker of histamine H2-receptors." | 7.68 | [Effectiveness of lecedil (famotidine) in the therapy of patients with peptic ulcer]. ( Grebenev, AL; Kornienko, AA; Sheptulin, AA; Smakov, GM; Trukhmanov, AS, 1993) |
| "The acute effects of histamine H2 receptor antagonist, famotidine, on hepatic hemodynamics were studied in six normal volunteers and eight patients with chronic liver disease, and its chronic effects on peptic ulcer, portal hemodynamics, and hepatic function were studied in 20 patients with chronic liver disease and peptic ulcer (16 with gastric ulcer, four with duodenal ulcer)." | 7.67 | Effect of famotidine on hepatic hemodynamics and peptic ulcer. ( Goto, N; Nomura, F; Ohnishi, K; Ohtsuki, T; Okuda, K; Saito, M; Suzuki, N; Takashi, M, 1987) |
| " Pharmacokinetic parameters were calculated assuming a one-compartment model." | 6.67 | Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. ( Aoki, S; Ashida, K; Manago, M; Mino, M; Nagita, A; Suzuki, K, 1994) |
| "In the treatment of gastroduodenal ulceration both the reduction of gastric acidity and the defence of mucosal membrane have an important role." | 6.39 | [Famotidine in the treatment of gastroduodenal ulcer]. ( Fehér, J; Lengyel, G, 1994) |
| "Famotidine is a highly selective histamine H2-receptor antagonist." | 6.38 | Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. ( Goa, KL; Grant, SM; Langtry, HD, 1989) |
| "Famotidine is a new histamine H2-receptor antagonist." | 6.37 | Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. ( Campoli-Richards, DM; Clissold, SP, 1986) |
| "The aim of this work was to prepare a combined drug dosage form of famotidine (FAM) and quercetin (QRT) to augment treatment of gastric ulcer." | 5.42 | Evaluation of combined famotidine with quercetin for the treatment of peptic ulcer: in vivo animal study. ( Abourehab, MA; Ahmed, OA; Khaled, KA; Sarhan, HA, 2015) |
| "Omeprazole was superior to famotidine with less gastrointestinal symptoms and recurrent ulcers/erosions in patients using 24-week low-dose aspirin." | 5.40 | Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study. ( Chan, HH; Chen, WC; Cheng, JS; Chiang, PH; Lai, KH; Li, YD; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, EM, 2014) |
| "It was found that patients with gastroduodenal ulcer have metabolic, less frequently hypercapnic acidosis with suppressed gastric secretion of HCO3-." | 5.31 | [Relations of acid-base balance and gastric secretion of hydrogen carbonate ions in patients with peptic ulcer]. ( Ivashkina, TG; Kulikov, AN; Malov, IuS, 2001) |
| "Famotidine clearance was reduced only in patients with decompensated cirrhosis, probably because of concomitant renal impairment." | 5.28 | Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer. ( Ohnishi, K, 1990) |
| "From January 2012 to 2016, long-termed thienopyridine users with a peptic ulcer history who did not have peptic ulcers at initial endoscopy were randomly assigned to receive either famotidine (40 mg, before bedtime) or placebo (before bedtime) for 6 months." | 5.24 | Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial. ( Chen, WC; Cheng, JS; Hsu, PI; Kao, SS; Lai, KH; Liu, CP; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC, 2017) |
| " Patients without ulcers or erosive oesophagitis on endoscopy at baseline were randomly assigned by computer-generated randomisation sequence to receive famotidine 20 mg twice daily (n=204) or placebo twice daily (n=200)." | 5.14 | Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. ( Bezlyak, V; McCloskey, C; Prasad, R; Taha, AS, 2009) |
| "Little is known about the efficacy of H(2)-receptor antagonists in preventing recurrence of aspirin-related peptic ulcers." | 5.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
| "The healing rate of gastroduodenal ulcers during continuous use of low-dose aspirin was greater than 80% in both the PPI group and the H2RA group, with no significant difference between the two groups." | 5.14 | Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. ( Kato, M; Nema, H, 2010) |
| "The aim of this study was to evaluate the effect of famotidine, a histamine receptor antagonist on corpus gastritis in patients with peptic ulcer disease." | 5.11 | Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease. ( Chayama, K; Haruma, K; Hata, J; Ito, M; Kamada, T; Kawamura, Y; Kusunoki, H; Sugiu, K; Tanaka, S, 2005) |
| "A total of 120 patients with peptic ulcer and non-ulcer dyspepsia were randomly assigned to a 2-week course of either: famotidine 40 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (FAT group; n = 60); or omeprazole 20 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (OAT group; n = 60)." | 5.09 | Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. ( Changchien, CS; Chen, JJ; Hsu, CC; Hu, TH; Lu, SN, 2001) |
| " pylori-positive patients who had peptic ulcers or reflux oesophagitis were treated for 3 years with either omeprazole (20 mg/day) alone (n=7) or with omeprazole for primary therapy (8 weeks), followed by famotidine (40 mg/day) for maintenance therapy (n=134)." | 5.09 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. ( Mashiba, H; Matsumura, N; Okamoto, S; Sasaki, N; Taniyama, K; Uemura, N; Yamaguchi, S; Yamamoto, S, 2000) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 5.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "One hundred four patients with rheumatoid or osteoarthritis who had gastroduodenal ulceration received famotidine, 40 mg twice daily." | 5.08 | Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. ( Cottrell, J; Hawkey, CJ; Hudson, N; Mann, SG; Russell, RI; Sturrock, RD; Swanell, AJ; Taha, AS; Trye, P, 1997) |
| " Early indications that acid suppression was effective in the management of NSAID-related peptic ulcers came from studies showing that gastric ulcers could be healed by omeprazole in patients who continued to take NSAIDs." | 4.80 | Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression. ( Armstrong, D; Lad, R, 1999) |
| " The purpose of the present work was to characterize the interaction and investigate the protective effect of H2 blocker famotidine and gallic acid in combination against experimentally induced peptic ulcer." | 3.80 | Synergistic effect of the combination of gallic acid and famotidine in protection of rat gastric mucosa. ( Asokkumar, K; Sen, S; Sivashanmugam, AT; Subhadradevi, V; Umamaheswari, M, 2014) |
| " We conducted a cross-sectional study to compare the prevalence of gastroduodenal ulcers or erosions in patients taking LDA with either 40 mg/day of famotidine or 15 mg/day of lansoprazole for at least three months." | 3.79 | Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2. ( Kadota, J; Murakami, K; Tamura, A, 2013) |
| "The purpose of this study was to assess the incidence and clinical significance of famotidine-associated thrombocytopenia in the trauma patient population." | 3.77 | Famotidine use and thrombocytopenia in the trauma patient. ( Compoginis, JM; Gaspard, D; Obaid, A, 2011) |
| "In an open clinical endoscopically controlled study in 30 consecutive patients with rheumatic diseases complicated by the ulcerative and erosive form of gastroduodenopathy induced by non-steroidal antiinflammatory drugs and oesophagitis, after four weeks treatment with oral famotidine (one dose of 40 mg/day) confirmed a significant improvement of the mean oesophageal (0." | 3.69 | [Famotidine in the treatment of gastropathy induced by non-steroidal antirheumatic agents]. ( Hyrdel, R; Rovenský, J; Rybár, I, 1997) |
| "4 mg/kg as an intravenous infusion over 5 min (a dosage previously used to test drug interactions with cimetidine and ranitidine) were evaluated in 7 patients with chronic obstructive pulmonary disease (COPD) and peptic ulcer disease before and after 8 days' treatment with famotidine 40mg at night." | 3.68 | Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease. ( Dal Negro, R; Pomari, C; Turco, P, 1993) |
| "A total of 30 patients (29 with peptic ulcer and 2 with erosive gastroduodenitis) received lecedil, a new famotidine blocker of histamine H2-receptors." | 3.68 | [Effectiveness of lecedil (famotidine) in the therapy of patients with peptic ulcer]. ( Grebenev, AL; Kornienko, AA; Sheptulin, AA; Smakov, GM; Trukhmanov, AS, 1993) |
| "The effect of ranitidine 300 mg po given at 1800 h (famotidine 40 mg/cimetidine 800 mg) on the night time gastric pH was tested using longterm intragastric pH monitoring in 27 patients with and 32 patients without liver cirrhosis." | 3.67 | Frequent non-response to histamine H2-receptor antagonists in cirrhotics. ( Bode, JC; Klotz, U; Krishna, DR; Walker, S, 1989) |
| "The acute effects of histamine H2 receptor antagonist, famotidine, on hepatic hemodynamics were studied in six normal volunteers and eight patients with chronic liver disease, and its chronic effects on peptic ulcer, portal hemodynamics, and hepatic function were studied in 20 patients with chronic liver disease and peptic ulcer (16 with gastric ulcer, four with duodenal ulcer)." | 3.67 | Effect of famotidine on hepatic hemodynamics and peptic ulcer. ( Goto, N; Nomura, F; Ohnishi, K; Ohtsuki, T; Okuda, K; Saito, M; Suzuki, N; Takashi, M, 1987) |
| " During the late period (7-9 h post-dose), when the subjects were dosed with placebo, mean gastric acid output was 41." | 2.68 | Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man. ( Cottrell, J; Grimley, CE; Loft, DE; Mann, SG; Nwokolo, CU; Stauffer, L; West, JM, 1996) |
| "Cimetidine-treated group consisted of 15, famotidine-treated group of 18, ranitidine-treated group of 19, and antacid-treated group of 5 patients." | 2.67 | Comparative efficacy of cimetidine, famotidine, ranitidine, and mylanta in postoperative stress ulcers. Gastric pH control and ulcer prevention in patients undergoing coronary artery bypass graft surgery. ( Castellano, J; Lamothe, PH; Lemole, GM; McNicholas, KW; Rao, E; Serra, AJ; Woronick, CL, 1991) |
| " Pharmacokinetic parameters were calculated assuming a one-compartment model." | 2.67 | Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. ( Aoki, S; Ashida, K; Manago, M; Mino, M; Nagita, A; Suzuki, K, 1994) |
| " Dosage requirements vary according to age and clinical condition, and children require a relatively higher drug dosage (mg/kg) than adults." | 2.39 | Do H2 receptor antagonists have a therapeutic role in childhood? ( Kelly, DA, 1994) |
| "In the treatment of gastroduodenal ulceration both the reduction of gastric acidity and the defence of mucosal membrane have an important role." | 2.39 | [Famotidine in the treatment of gastroduodenal ulcer]. ( Fehér, J; Lengyel, G, 1994) |
| " While very safe, clinicians need to know correct dosing guidelines, drug interactions, and side effect profiles." | 2.38 | The clinical use of histamine-2 receptor antagonists. ( Michocki, RJ; Richardson, JP, 1992) |
| "Famotidine is a highly selective histamine H2-receptor antagonist." | 2.38 | Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. ( Goa, KL; Grant, SM; Langtry, HD, 1989) |
| "Famotidine is a new histamine H2-receptor antagonist." | 2.37 | Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. ( Campoli-Richards, DM; Clissold, SP, 1986) |
| "Famotidine is an even more potent H2 receptor antagonist, and initial clinical studies are promising." | 2.37 | Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's. ( Mahachai, V; Thomson, AB, 1987) |
| " This single evening dosage regimen produces effective healing of gastric and duodenal ulceration; maintenance of healing can then be achieved satisfactorily with 20 mg in the evening." | 2.37 | The place of famotidine in anti-ulcer therapy. ( Mann, SG, 1987) |
| "The aim of this work was to prepare a combined drug dosage form of famotidine (FAM) and quercetin (QRT) to augment treatment of gastric ulcer." | 1.42 | Evaluation of combined famotidine with quercetin for the treatment of peptic ulcer: in vivo animal study. ( Abourehab, MA; Ahmed, OA; Khaled, KA; Sarhan, HA, 2015) |
| "Omeprazole was superior to famotidine with less gastrointestinal symptoms and recurrent ulcers/erosions in patients using 24-week low-dose aspirin." | 1.40 | Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study. ( Chan, HH; Chen, WC; Cheng, JS; Chiang, PH; Lai, KH; Li, YD; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, EM, 2014) |
| " History of uncomplicated peptic ulcer and frequent dosing were additional factors associated with non-adherence to NSAIDs." | 1.38 | Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients. ( Gonzalez, MA; Lanas, A; Polo-Tomás, M; Roncales, P; Zapardiel, J, 2012) |
| "Ampicillin (800 mg/kg) was given p." | 1.36 | Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats. ( Amagase, K; Kato, S; Ochi, A; Sugihara, T; Takeuchi, K, 2010) |
| "Diclofenac can cause gastric mucosal lesions, including ulcers, more easily than other NSAIDs." | 1.34 | Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis. ( Fukui, H; Takakura, Y; Yajima, H; Yamao, J, 2007) |
| "It was found that patients with gastroduodenal ulcer have metabolic, less frequently hypercapnic acidosis with suppressed gastric secretion of HCO3-." | 1.31 | [Relations of acid-base balance and gastric secretion of hydrogen carbonate ions in patients with peptic ulcer]. ( Ivashkina, TG; Kulikov, AN; Malov, IuS, 2001) |
| " The authors' five cases and the other seven previously reported emphasize the need for dosage adjustment of famotidine in elderly patients and in those with renal failure, and that these patients should be carefully monitored for development of central nervous system reactions, which sometimes could be very serious." | 1.30 | Central nervous system reactions associated with famotidine: report of five cases. ( Odeh, M; Oliven, A, 1998) |
| " cimetidine or famotidine for stress ulcer prophylaxis were reviewed during a two-month period in 1997, and information on demographics, dosage and duration of H2RA therapy, admission date, laboratory test values, and adverse drug reactions was collected." | 1.30 | Using multiple pharmacoeconomic methods to conduct a cost-effectiveness analysis of histamine H2-receptor antagonists. ( Blayney-Chandramouli, J; McCoy, S; Mutnick, A, 1998) |
| "Hyperemesis gravidarum is the most severe spectrum of gastrointestinal complaints in pregnant women." | 1.30 | Helicobacter pylori infection and persistent hyperemesis gravidarum. ( Jacoby, EB; Porter, KB, 1999) |
| " However, there are possibilities that long term administration of H2-RA might cause changes in intragastric environment." | 1.28 | [Problems in ulcer surgery after the introduction of H2-receptor antagonists]. ( Akimoto, H; Aoki, T; Fukuchi, Y; Ito, A; Kashiwagi, H; Kashiwagi, T; Kimura, K, 1992) |
| "Famotidine clearance was reduced only in patients with decompensated cirrhosis, probably because of concomitant renal impairment." | 1.28 | Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer. ( Ohnishi, K, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (22.92) | 18.7374 |
| 1990's | 39 (40.63) | 18.2507 |
| 2000's | 15 (15.63) | 29.6817 |
| 2010's | 19 (19.79) | 24.3611 |
| 2020's | 1 (1.04) | 2.80 |
| Authors | Studies |
|---|---|
| El-Dakroury, WA | 1 |
| Zewail, MB | 1 |
| Elsabahy, M | 1 |
| Shabana, ME | 1 |
| Asaad, GF | 1 |
| Tamura, A | 1 |
| Murakami, K | 1 |
| Kadota, J | 1 |
| Asokkumar, K | 1 |
| Sen, S | 1 |
| Umamaheswari, M | 1 |
| Sivashanmugam, AT | 1 |
| Subhadradevi, V | 1 |
| He, Y | 1 |
| Chan, EW | 1 |
| Man, KK | 1 |
| Lau, WC | 1 |
| Leung, WK | 1 |
| Ho, LM | 1 |
| Wong, IC | 1 |
| Nichitaĭlo, ME | 1 |
| Chen, WC | 2 |
| Li, YD | 1 |
| Chiang, PH | 1 |
| Tsay, FW | 2 |
| Chan, HH | 1 |
| Tsai, WL | 1 |
| Tsai, TJ | 2 |
| Wang, EM | 1 |
| Cheng, JS | 2 |
| Lai, KH | 2 |
| Takeuchi, T | 2 |
| Ota, K | 1 |
| Harada, S | 1 |
| Kojima, Y | 1 |
| Inoue, T | 1 |
| Iwakiri, R | 1 |
| Sakata, Y | 2 |
| Fujimoto, K | 2 |
| Fujita, T | 1 |
| Azuma, T | 1 |
| Higuchi, K | 3 |
| Abourehab, MA | 1 |
| Khaled, KA | 1 |
| Sarhan, HA | 1 |
| Ahmed, OA | 1 |
| Chan, FK | 1 |
| Kyaw, M | 1 |
| Tanigawa, T | 1 |
| Cheong, PK | 1 |
| Lee, V | 1 |
| Kinoshita, Y | 2 |
| Naito, Y | 1 |
| Watanabe, T | 1 |
| Ching, JY | 1 |
| Lam, K | 1 |
| Lo, A | 1 |
| Chan, H | 1 |
| Lui, R | 1 |
| Tang, RS | 1 |
| Tse, YK | 1 |
| Handa, O | 1 |
| Nebiki, H | 1 |
| Wu, JC | 1 |
| Abe, T | 1 |
| Mishiro, T | 1 |
| Ng, SC | 1 |
| Arakawa, T | 1 |
| Hsu, PI | 1 |
| Wu, DC | 1 |
| Liu, CP | 1 |
| Wang, HM | 1 |
| Tsai, KW | 1 |
| Kao, SS | 1 |
| Hawkey, CJ | 3 |
| Taha, AS | 3 |
| McCloskey, C | 1 |
| Prasad, R | 1 |
| Bezlyak, V | 1 |
| Ng, FH | 1 |
| Wong, SY | 1 |
| Lam, KF | 1 |
| Chu, WM | 1 |
| Chan, P | 1 |
| Ling, YH | 1 |
| Kng, C | 1 |
| Yuen, WC | 1 |
| Lau, YK | 1 |
| Kwan, A | 1 |
| Wong, BC | 1 |
| Amagase, K | 1 |
| Ochi, A | 1 |
| Sugihara, T | 1 |
| Kato, S | 1 |
| Takeuchi, K | 1 |
| Umegaki, E | 1 |
| Yoda, Y | 1 |
| Tokioka, S | 1 |
| Murano, M | 1 |
| Nema, H | 1 |
| Kato, M | 1 |
| Hiraishi, H | 1 |
| Maeda, M | 1 |
| Sasai, T | 1 |
| Kanke, K | 1 |
| Shimada, T | 1 |
| Drozdov, VN | 1 |
| Kim, VA | 1 |
| Lazebnik, LB | 1 |
| Compoginis, JM | 1 |
| Gaspard, D | 1 |
| Obaid, A | 1 |
| Lanas, A | 1 |
| Polo-Tomás, M | 1 |
| Roncales, P | 1 |
| Gonzalez, MA | 1 |
| Zapardiel, J | 1 |
| Wu, CS | 1 |
| Sung, SF | 1 |
| Tong, SH | 1 |
| Ong, CT | 1 |
| Szabó, IL | 1 |
| Czimmer, J | 1 |
| Szolcsányi, J | 1 |
| Mózsik, G | 1 |
| Mak, SK | 1 |
| Loo, CK | 1 |
| Wong, AM | 1 |
| Wong, PN | 1 |
| Lo, KY | 1 |
| Tong, GM | 1 |
| Lam, EK | 1 |
| Wong, AK | 1 |
| Coursol, CJ | 1 |
| Sanzari, SE | 1 |
| Miyake, K | 1 |
| Ueki, N | 1 |
| Suzuki, K | 2 |
| Shinji, Y | 1 |
| Kusunoki, M | 1 |
| Hiratsuka, T | 1 |
| Nishigaki, H | 1 |
| Tatsuguchi, A | 1 |
| Futagami, S | 1 |
| Wada, K | 1 |
| Tsukui, T | 1 |
| Nakajima, A | 1 |
| Yoshino, S | 1 |
| Sakamoto, C | 1 |
| Kamada, T | 1 |
| Hata, J | 1 |
| Kusunoki, H | 1 |
| Sugiu, K | 1 |
| Ito, M | 1 |
| Tanaka, S | 1 |
| Kawamura, Y | 1 |
| Chayama, K | 1 |
| Haruma, K | 1 |
| Adachi, K | 1 |
| Komazawa, Y | 1 |
| Mihara, T | 1 |
| Azumi, T | 1 |
| Fujisawa, T | 1 |
| Katsube, T | 1 |
| Furuta, K | 1 |
| Gostishchev, VK | 1 |
| Evseev, MA | 1 |
| Belousov, IuB | 1 |
| Karpov, OI | 1 |
| Belousov, DIu | 1 |
| Beketov, AS | 1 |
| Yajima, H | 1 |
| Yamao, J | 1 |
| Fukui, H | 1 |
| Takakura, Y | 1 |
| Dammann, HG | 1 |
| Walter, TA | 1 |
| Müller, P | 1 |
| Simon, B | 1 |
| Mori, H | 1 |
| Murakami, M | 1 |
| Saita, H | 1 |
| Takahashi, Y | 1 |
| Kusaka, S | 1 |
| Asagoe, K | 1 |
| Dekigai, H | 1 |
| Matsumoto, M | 1 |
| Seki, M | 1 |
| Mizuno, M | 1 |
| Maeda, S | 1 |
| Okhlobystin, AV | 1 |
| Baghaie, AA | 1 |
| Mojtahedzadeh, M | 1 |
| Levine, RL | 1 |
| Fromm, RE | 1 |
| Guntupalli, KK | 1 |
| Opekun, AR | 1 |
| Kelly, DA | 1 |
| Nagita, A | 1 |
| Manago, M | 1 |
| Aoki, S | 1 |
| Mino, M | 1 |
| Ashida, K | 1 |
| Lengyel, G | 1 |
| Fehér, J | 1 |
| Grebenev, AL | 2 |
| Sheptulin, AA | 1 |
| Smakov, GM | 1 |
| Kornienko, AA | 1 |
| Trukhmanov, AS | 1 |
| Wilson, P | 1 |
| Clark, GW | 1 |
| Anselmino, M | 1 |
| Welch, NT | 1 |
| Singh, S | 1 |
| Perdikis, G | 1 |
| Hinder, RA | 1 |
| Vargas, V | 1 |
| Castro, J | 1 |
| del Solar, F | 1 |
| Sanhueza, H | 1 |
| Aguila, R | 1 |
| Luppi, M | 1 |
| Fernández, D | 1 |
| Rojas, M | 1 |
| Dal Negro, R | 1 |
| Pomari, C | 1 |
| Turco, P | 1 |
| Golochevskaia, VS | 1 |
| Shonová, O | 1 |
| Petr, P | 1 |
| Lawless, C | 1 |
| Force, RW | 1 |
| Grimley, CE | 1 |
| West, JM | 1 |
| Loft, DE | 1 |
| Cottrell, J | 2 |
| Mann, SG | 3 |
| Stauffer, L | 1 |
| Nwokolo, CU | 1 |
| Singh, G | 1 |
| Fries, JF | 1 |
| Nogaller, AM | 1 |
| Butov, MA | 1 |
| Luniakov, AS | 1 |
| Hudson, N | 2 |
| Russell, RI | 2 |
| Trye, P | 1 |
| Swanell, AJ | 1 |
| Sturrock, RD | 2 |
| Graham, DY | 1 |
| Palop, D | 1 |
| Romero, A | 1 |
| Villamayor, F | 1 |
| Conejo, L | 1 |
| Sacristán, A | 1 |
| Ortiz, JA | 1 |
| Moayyedi, P | 1 |
| Haga, Y | 1 |
| Nakatsura, T | 1 |
| Shibata, Y | 1 |
| Sameshima, H | 1 |
| Nakamura, Y | 1 |
| Tanimura, M | 1 |
| Ogawa, M | 1 |
| Rybár, I | 1 |
| Rovenský, J | 1 |
| Hyrdel, R | 1 |
| Odeh, M | 1 |
| Oliven, A | 1 |
| McCoy, S | 1 |
| Blayney-Chandramouli, J | 1 |
| Mutnick, A | 1 |
| Dahill, S | 1 |
| Morran, C | 1 |
| Lee, FD | 1 |
| Lad, R | 1 |
| Armstrong, D | 1 |
| Jacoby, EB | 1 |
| Porter, KB | 1 |
| Uemura, N | 1 |
| Okamoto, S | 1 |
| Yamamoto, S | 1 |
| Matsumura, N | 1 |
| Yamaguchi, S | 1 |
| Mashiba, H | 1 |
| Sasaki, N | 1 |
| Taniyama, K | 1 |
| Malov, IuS | 1 |
| Kulikov, AN | 1 |
| Ivashkina, TG | 1 |
| Hsu, CC | 1 |
| Chen, JJ | 1 |
| Hu, TH | 1 |
| Lu, SN | 1 |
| Changchien, CS | 1 |
| Maev, IV | 1 |
| Samsonov, A | 1 |
| Val'tova, ED | 1 |
| Ismailova, MZ | 1 |
| Ovchinnikova, NI | 1 |
| Wade, EE | 1 |
| Rebuck, JA | 1 |
| Healey, MA | 1 |
| Rogers, FB | 1 |
| Akimoto, H | 1 |
| Kashiwagi, H | 1 |
| Ito, A | 1 |
| Fukuchi, Y | 1 |
| Kimura, K | 1 |
| Kashiwagi, T | 1 |
| Aoki, T | 2 |
| Stuart, RC | 1 |
| Hehir, D | 1 |
| Michocki, RJ | 1 |
| Richardson, JP | 1 |
| Miagkova, LP | 1 |
| Kkhorshed, AM | 1 |
| Grigor'ev, PIa | 1 |
| Isakov, VA | 1 |
| Iakovenko, EP | 1 |
| Davydov, SM | 1 |
| Vasil'eva, ZI | 1 |
| Hoshino, R | 1 |
| Kagoshima, M | 1 |
| Shimada, H | 1 |
| Inatomi, N | 1 |
| Nagaya, H | 1 |
| Takami, K | 1 |
| Shino, A | 1 |
| Satoh, H | 1 |
| Kaminsky, R | 1 |
| Moriarty, TM | 1 |
| Bodine, J | 1 |
| Wolf, DE | 1 |
| Davidson, M | 1 |
| Lamothe, PH | 1 |
| Rao, E | 1 |
| Serra, AJ | 1 |
| Castellano, J | 1 |
| Woronick, CL | 1 |
| McNicholas, KW | 1 |
| Lemole, GM | 1 |
| Ahmad, S | 1 |
| Ohnishi, K | 2 |
| Walt, RP | 1 |
| De Natale, G | 1 |
| De Natale, F | 1 |
| Marino, A | 1 |
| Walker, S | 1 |
| Krishna, DR | 1 |
| Klotz, U | 1 |
| Bode, JC | 1 |
| Langtry, HD | 1 |
| Grant, SM | 1 |
| Goa, KL | 1 |
| Campoli-Richards, DM | 1 |
| Clissold, SP | 1 |
| Saito, M | 1 |
| Nomura, F | 1 |
| Okuda, K | 1 |
| Suzuki, N | 1 |
| Ohtsuki, T | 1 |
| Goto, N | 1 |
| Takashi, M | 1 |
| Thomson, AB | 1 |
| Mahachai, V | 1 |
| Saigenji, K | 1 |
| Fukutomi, H | 1 |
| Nakazawa, S | 1 |
| Weir, DG | 1 |
| Blanco, M | 1 |
| Pajares, JM | 1 |
| Jimenez, ML | 1 |
| Lopez-Brea, M | 1 |
| Berta, L | 1 |
| Dusio, P | 1 |
| Fortunati, N | 1 |
| Fazzari, A | 1 |
| Crua, MR | 1 |
| Frairia, R | 1 |
| Gaidano, G | 1 |
| Gugler, R | 2 |
| Polloni, A | 1 |
| Marchi, S | 1 |
| Greco, A | 1 |
| Cipparrone, G | 1 |
| Costa, F | 1 |
| Bellini, M | 1 |
| Maltinti, G | 1 |
| Lewis, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)[NCT01408186] | Phase 3 | 264 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
17 reviews available for famotidine and Peptic Ulcer
| Article | Year |
|---|---|
[Strategy to manage low dose aspirin-induced gastrointestinal injury].
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Famotid | 2011 |
Molecular pharmacological approaches to effects of capsaicinoids and of classical antisecretory drugs on gastric basal acid secretion and on indomethacin-induced gastric mucosal damage in human healthy subjects (mini review).
Topics: Adult; Afferent Pathways; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Atrop | 2013 |
Do H2 receptor antagonists have a therapeutic role in childhood?
Topics: Adolescent; Child; Child, Preschool; Cimetidine; Cystic Fibrosis; Drug Interactions; Famotidine; Gas | 1994 |
[Famotidine in the treatment of gastroduodenal ulcer].
Topics: Famotidine; Humans; Peptic Ulcer | 1994 |
[Clinical aspects of Kvamatel (famotidine) administration].
Topics: Anti-Ulcer Agents; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Peptic Ulc | 1996 |
Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Gastric Juic | 1999 |
H(2) antagonist-induced thrombocytopenia: is this a real phenomenon?
Topics: Cimetidine; Critical Care; Famotidine; Histamine H2 Antagonists; Humans; Peptic Ulcer; Ranitidine; R | 2002 |
The clinical use of histamine-2 receptor antagonists.
Topics: Cimetidine; Drug Evaluation; Famotidine; Gastroesophageal Reflux; Humans; Nizatidine; Peptic Ulcer; | 1992 |
[Histamine H2 receptor blockaders: possibilities and prognosis in the use of stage III-IV preparations in the therapy of internal diseases].
Topics: Cimetidine; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans; Peptic Ulcer; Ranitidine | 1991 |
[Famotidine--a new histamine H2 receptor blockader].
Topics: Cimetidine; Famotidine; Gastric Acid; Gastric Mucosa; Humans; Peptic Ulcer; Receptors, Histamine H2 | 1991 |
Clinical importance of the new H2-antagonists.
Topics: Animals; Famotidine; Histamine H2 Antagonists; Humans; Nizatidine; Peptic Ulcer; Piperidines; Thiazo | 1989 |
[Drugs used in the therapy of peptic ulcer with special reference to H2 receptor blockaders].
Topics: Antacids; Anti-Ulcer Agents; Cimetidine; Famotidine; Female; Histamine H2 Antagonists; Humans; Male; | 1989 |
Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
Topics: Famotidine; Histamine H2 Antagonists; Humans; Peptic Ulcer | 1989 |
Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
Topics: Animals; Famotidine; Histamine H2 Antagonists; Humans; Kinetics; Peptic Ulcer; Thiazoles; Zollinger- | 1986 |
Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's.
Topics: Alprostadil; Antacids; Anti-Ulcer Agents; Cimetidine; Drug Resistance; Enprostil; Famotidine; Histam | 1987 |
Peptic ulceration.
Topics: Adenosine Triphosphatases; Anti-Ulcer Agents; Famotidine; H(+)-K(+)-Exchanging ATPase; Histamine H2 | 1988 |
The place of famotidine in anti-ulcer therapy.
Topics: Famotidine; Humans; Peptic Ulcer | 1987 |
30 trials available for famotidine and Peptic Ulcer
| Article | Year |
|---|---|
Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Diterpenes; Famotidine; Female; Histamine H2 Antagonists; Humans; | 2014 |
Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Famotidine; Female; Hemoglobins; Histamine H2 | 2017 |
Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Atherosclerosis; Clopidogrel; Double-Blind Method; F | 2017 |
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Double-Blind Me | 2009 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2010 |
[Modern approach to the prevention and treatment of NSAID-gastropathy].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Diclofenac; Famotidine; Gastric Mucosa; | 2011 |
Molecular pharmacological approaches to effects of capsaicinoids and of classical antisecretory drugs on gastric basal acid secretion and on indomethacin-induced gastric mucosal damage in human healthy subjects (mini review).
Topics: Adult; Afferent Pathways; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Atrop | 2013 |
Impact of stress ulcer prophylaxis algorithm study.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-Ulcer Agents; Drug Administration Schedule; Famotid | 2005 |
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2005 |
Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Ulcer Agents; Famotidine; Female; Gastric Acid; Gastritis; H | 2005 |
Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
Topics: Adult; Chromatography, High Pressure Liquid; Cimetidine; Cross-Over Studies; Famotidine; Follow-Up S | 2005 |
Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Ulce | 1995 |
Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients: results of a prospective, randomized, crossover study.
Topics: Adult; Aged; Critical Illness; Cross-Over Studies; Famotidine; Female; Gastric Acid; Humans; Hydroge | 1995 |
Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers.
Topics: Administration, Oral; Adolescent; Biological Availability; Child; Famotidine; Gastric Acid; Gastric | 1994 |
Comparison of an intravenous bolus of famotidine and Mylanta II for the control of gastric pH in critically ill patients.
Topics: Adult; Aluminum Hydroxide; Antacids; Critical Illness; Drug Combinations; Famotidine; Female; Gastri | 1993 |
[Comparative study of famotidine vs ranitidine in critically ill patients in mechanical ventilation].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Critical Care; Double-Blind Method; Famotidine; Femal | 1993 |
Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man.
Topics: Administration, Oral; Adult; Analysis of Variance; Anti-Ulcer Agents; Cross-Over Studies; Famotidine | 1996 |
Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Duodenal Ulcer; Famotidine; | 1997 |
Quadruple therapy: the golden bullet or a drug too far?
Topics: Antacids; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Helicobacter Infections; Helicob | 1996 |
Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Double-Blind Meth | 1999 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Topics: Anti-Ulcer Agents; Enzyme Inhibitors; Famotidine; Gastric Mucosa; Gastritis; Gastroscopy; Helicobact | 2000 |
Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combin | 2001 |
[Efficiency of quamatel in combination with device sound stimulation of the gastroduodenal zone in ulcer patients].
Topics: Acoustic Stimulation; Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Antifungal Agents; Combined | 2001 |
[Famotidine--a new histamine H2 receptor blockader].
Topics: Cimetidine; Famotidine; Gastric Acid; Gastric Mucosa; Humans; Peptic Ulcer; Receptors, Histamine H2 | 1991 |
Comparative efficacy of cimetidine, famotidine, ranitidine, and mylanta in postoperative stress ulcers. Gastric pH control and ulcer prevention in patients undergoing coronary artery bypass graft surgery.
Topics: Aged; Aluminum Hydroxide; Antacids; Cimetidine; Coronary Artery Bypass; Drug Combinations; Famotidin | 1991 |
Treatment of upper gastro-intestinal bleeding with the H2-receptor antagonist famotidine.
Topics: Anti-Ulcer Agents; Clinical Trials as Topic; Famotidine; Histamine H2 Antagonists; Humans; Multicent | 1989 |
Effect of acid inhibition on Campylobacter pylori.
Topics: Adult; Campylobacter; Campylobacter Infections; Duodenitis; Famotidine; Female; Gastric Acid; Gastri | 1988 |
Famotidine in the short-term treatment of duodenal ulcer and of concomitant peptic lesions: comparison with cimetidine.
Topics: Cimetidine; Duodenal Ulcer; Famotidine; Female; Humans; Male; Middle Aged; Peptic Ulcer; Thiazoles | 1988 |
Summary of the 30th meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee January 16-17, 1986.
Topics: Aluminum; Cimetidine; Clinical Trials as Topic; Duodenal Ulcer; Famotidine; Humans; Peptic Ulcer; Su | 1986 |
51 other studies available for famotidine and Peptic Ulcer
| Article | Year |
|---|---|
Famotidine-loaded solid self-nanoemulsifying drug delivery system demonstrates exceptional efficiency in amelioration of peptic ulcer.
Topics: Animals; Drug Delivery Systems; Famotidine; Microscopy, Electron, Scanning; Peptic Ulcer; Rats | 2022 |
Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cohort Studies; Cross-Sectional Studies; Drug Administration Sched | 2013 |
Synergistic effect of the combination of gallic acid and famotidine in protection of rat gastric mucosa.
Topics: Animals; Anti-Ulcer Agents; Antioxidants; Disease Models, Animal; Drug Synergism; Drug Therapy, Comb | 2014 |
Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Anti-Inflammatory | 2014 |
[Prophylaxis of an acute postoperative pancreatitis and the stress ulcers occurrence after operations, performed on organs of hepatopancreatoduodenal zone, using miniinvasive and open access].
Topics: Acute Disease; Drug Administration Schedule; Drug Dosage Calculations; Duodenal Ulcer; Endoscopy, Ga | 2014 |
Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; F | 2014 |
Evaluation of combined famotidine with quercetin for the treatment of peptic ulcer: in vivo animal study.
Topics: Alginates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antioxidants; Chemis | 2015 |
NSAIDs and aspirin: notorious or FAMOUS?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase Inhibitors; Esop | 2009 |
Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats.
Topics: 16,16-Dimethylprostaglandin E2; Acetamides; Ampicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer A | 2010 |
Protective effect of roxatidine against indomethacin-induced small intestinal mucosal injury in rats.
Topics: Animals; Anti-Ulcer Agents; Cimetidine; Disease Models, Animal; Famotidine; Histamine H2 Antagonists | 2010 |
Famotidine use and thrombocytopenia in the trauma patient.
Topics: California; Dose-Response Relationship, Drug; Famotidine; Female; Follow-Up Studies; Histamine H2 An | 2011 |
Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Famotidine; Female; Humans; Male; | 2012 |
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulc | 2012 |
Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 2002 |
[Antisecretory therapy as a component of hemostasis in acute gastroduodenal ulcer bleedings].
Topics: Acute Disease; Anti-Ulcer Agents; Famotidine; Gastrointestinal Agents; Histamine H2 Antagonists; Hum | 2005 |
[Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Th | 2007 |
Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis.
Topics: Adult; Aged; Alanine; Anti-Ulcer Agents; Bone Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; End | 2007 |
[H2 receptor antagonists and intragastric acidity].
Topics: Cimetidine; Drug Administration Schedule; Famotidine; Histamine Antagonists; Histamine H2 Antagonist | 1984 |
[Effects of protective agents on ulcer formation].
Topics: Adult; Animals; Cimetidine; Dogs; Duodenal Ulcer; Famotidine; Gastric Juice; Gastric Mucosa; Humans; | 1984 |
[Properties of a new drug famocid: indications and contraindications of its use?].
Topics: Contraindications; Duodenitis; Famotidine; Gastritis; Humans; Kidney; Liver; Peptic Ulcer | 1995 |
[Effectiveness of lecedil (famotidine) in the therapy of patients with peptic ulcer].
Topics: Adult; Famotidine; Female; Humans; Male; Middle Aged; Peptic Ulcer; Treatment Outcome | 1993 |
Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease.
Topics: Cimetidine; Drug Interactions; Famotidine; Humans; Infusions, Intravenous; Lung Diseases, Obstructiv | 1993 |
[Ulfamid Krka (famotidine) in monotherapy of peptic ulcer].
Topics: Adult; Anti-Ulcer Agents; Famotidine; Female; Humans; Male; Peptic Ulcer; Prospective Studies | 1996 |
Prevention of NSAID-induced ulcers.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; | 1996 |
Famotidine to prevent peptic ulcer caused by NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Famotidine; Gastr | 1996 |
[Quamatel efficacy against ulcer].
Topics: Administration, Oral; Adolescent; Adult; Biopsy; Endoscopy, Digestive System; Famotidine; Follow-Up | 1996 |
High-dose famotidine for prevention of NSAID ulcers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Famotidine; Humans; Peptic Ulcer | 1997 |
Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Topics: Animals; Benzenesulfonates; Cimetidine; Dose-Response Relationship, Drug; Ethanol; Famotidine; Femal | 1997 |
Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Carcinoid Tumor; Famotidine; Hist | 1998 |
[Famotidine in the treatment of gastropathy induced by non-steroidal antirheumatic agents].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Esophagitis; Famotidine; Female; Histamine H2 Antagonists; | 1997 |
Central nervous system reactions associated with famotidine: report of five cases.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Brain Diseases; Famotidine; Female; Histamine H2 Antagon | 1998 |
Using multiple pharmacoeconomic methods to conduct a cost-effectiveness analysis of histamine H2-receptor antagonists.
Topics: Cimetidine; Cost-Benefit Analysis; Decision Trees; Famotidine; Female; Histamine H2 Antagonists; Hum | 1998 |
Helicobacter pylori infection and persistent hyperemesis gravidarum.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Famotidine | 1999 |
[Relations of acid-base balance and gastric secretion of hydrogen carbonate ions in patients with peptic ulcer].
Topics: Acid-Base Equilibrium; Acidosis; Adult; Anti-Ulcer Agents; Bicarbonates; Famotidine; Female; Gastric | 2001 |
[Problems in ulcer surgery after the introduction of H2-receptor antagonists].
Topics: Animals; Cell Count; Famotidine; Gastric Acid; Gastrins; Histamine H2 Antagonists; Humans; Hyperplas | 1992 |
Comparative efficacy of cimetidine, famotidine, ranitidine, and mylanta in postoperative stress ulcers.
Topics: Aluminum Hydroxide; Antacids; Cimetidine; Drug Combinations; Famotidine; Humans; Magnesium Hydroxide | 1992 |
[Effects of 3-hydroxymethyl-2-methylimidazo [2, 1-b] benzothiazole (NIK-228) on gastric acid secretion and various experimental peptic ulcers in rats].
Topics: Administration, Oral; Animals; Anti-Ulcer Agents; Benzothiazoles; Depression, Chemical; Dose-Respons | 1991 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esoph | 1991 |
Effect of famotidine on deficit symptoms of schizophrenia.
Topics: Adult; Famotidine; Humans; Male; Peptic Ulcer; Receptors, Histamine; Schizophrenia | 1990 |
Continuing advances in H2-antagonist therapy: focus on famotidine. Proceedings of a symposium. Nice, France, 14 October 1989.
Topics: Famotidine; Humans; Peptic Ulcer | 1990 |
Famotidine and cardiac arrhythmia.
Topics: Adult; Arrhythmia, Sinus; Famotidine; Humans; Male; Peptic Ulcer | 1991 |
Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer.
Topics: Adult; Chronic Disease; Famotidine; Female; Hepatitis; Humans; Liver Circulation; Liver Cirrhosis; L | 1990 |
Frequent non-response to histamine H2-receptor antagonists in cirrhotics.
Topics: Anti-Ulcer Agents; Cimetidine; Esophagitis, Peptic; Famotidine; Female; Gastric Acidity Determinatio | 1989 |
Famotidine: a further development in the modern treatment of peptic ulcer disease. Proceedings of a satellite symposium of the XIIth International Congress of Gastroenterology. Lisbon, September 19, 1984.
Topics: Famotidine; Histamine H2 Antagonists; Humans; Peptic Ulcer; Thiazoles | 1985 |
Famotidine: clinical applications of a new H2-receptor antagonist. May 16, 1986, Carmel, California.
Topics: Anti-Ulcer Agents; Famotidine; Histamine H2 Antagonists; Humans; Peptic Ulcer; Thiazoles | 1986 |
Effect of famotidine on hepatic hemodynamics and peptic ulcer.
Topics: Adult; Chronic Disease; Dye Dilution Technique; Famotidine; Female; Hemodynamics; Histamine H2 Antag | 1987 |
Famotidine: postmarketing clinical experience.
Topics: Adult; Famotidine; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Histamine H2 Anta | 1987 |
Plasma sex steroid transport and histamine H2-receptor antagonists. Clinical implications.
Topics: Adult; Cimetidine; Famotidine; Gonadal Steroid Hormones; Histamine H2 Antagonists; Hormones; Humans; | 1988 |
[New developments in ulcer therapy: famotidine, omeprazole misoprostol].
Topics: Alprostadil; Anti-Ulcer Agents; Famotidine; Humans; Misoprostol; Omeprazole; Peptic Ulcer; Thiazoles | 1986 |
[Peptic ulcer. New H2 blockers, prostaglandins, benzimidazoles].
Topics: Alprostadil; Anti-Ulcer Agents; Famotidine; Humans; Misoprostol; Omeprazole; Peptic Ulcer; Thiazoles | 1987 |
New H2-blockers: does more choice help?
Topics: Anti-Ulcer Agents; Cimetidine; Famotidine; Humans; Nizatidine; Peptic Ulcer; Ranitidine; Thiazoles | 1988 |